Skip to main content
logo
BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
56.05
+0.91 (1.65%)
At close: Oct 15, 2026, 4:00 PM EDT
56.11
+0.06 (0.11%)
After-hours: Oct 15, 2026, 7:30 PM EDT

BioMarin Pharmaceutical Revenue by Segment

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
Voxzogo
963.41M932.27M926.39M861.39M833.19M795.70M734.60M672.30MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Voxzogo Growth
15.63%17.16%26.11%28.13%37.60%48.76%56.36%71.99%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Naglazyme
507.33M500.94M484.87M474.87M484.77M487.90M479.50M467.80MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Naglazyme Growth
4.65%2.67%1.12%1.51%8.99%21.10%14.09%10.72%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Palynziq
458.73M429.50M432.94M407.94M389.54M371.90M354.60M342.40MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Palynziq Growth
17.76%15.49%22.09%19.14%17.79%17.21%16.64%18.68%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Brineura
195.47M192.80M185.69M184.69M173.69M170.30M169.30M164.90MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Brineura Growth
12.54%13.21%9.68%12.00%2.84%5.32%4.64%2.55%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Aldurazyme
183.28M196.18M208.44M198.44M215.44M197.60M183.90M187.60MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Aldurazyme Growth
-14.93%-0.72%13.34%5.78%65.21%49.58%40.17%48.65%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Kuvan
95.32M97.91M99.03M104.03M108.13M109.70M120.60M129.30MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Kuvan Growth
-11.85%-10.74%-17.88%-19.54%-24.96%-33.96%-33.26%-34.56%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Royalty and Other
42.01M49.12M53.49M49.93M46.51M43.98M44.48M45.90MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Royalty and Other Growth
-9.67%11.69%20.27%8.78%-1.26%-7.99%-4.96%0.44%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Roctavian
30.35M27.84M36.20M34.20M38.40M36.60M26.40M18.10MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Roctavian Growth
-20.96%-23.95%37.12%88.94%228.20%751.16%654.29%2,162.50%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade